Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Dec;16(6):695–699. doi: 10.1111/j.1365-2125.1983.tb02243.x

Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

J J Ibraheem, L Paalzow, P Tfelt-Hansen
PMCID: PMC1428366  PMID: 6419759

Abstract

Fifteen migraine patients were administered 2 mg ergotamine tartrate in a partial cross-over design as a single, oral tablet, rectal suppository and rectal solution. Eight of these patients were in a previous investigation given 0.5 mg ergotamine tartrate intravenously. The blood samples were taken up to 54 h after oral and suppository while it was followed for only 3 h after rectal solution. The chemical analysis was performed by applying h.p.l.c. method with a limit of sensitivity of 0.1 ng/ml ergotamine base in plasma. No ergotamine was detected in the blood samples after the oral route, whereas small and very variable quantities was found in blood after the rectal route. Regular calculation of bioavailability could therefore not be performed. An estimate of the maximal possible bioavailability was found to yield a mean value of 2% (tablets); 5% (suppositories) and 6% (rectal solution). Rectal solution elicited faster absorption and the extent of absorption was significantly higher (P less than 0.05) than for the suppository.

Full text

PDF
695

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aellig W. H., Nüesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm. 1977 Mar;15(3):106–112. [PubMed] [Google Scholar]
  2. Ala-Hurula V., Myllylä V. V., Arvela P., Heikkilä J., Kärki N., Hokkanen E. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol. 1979 Feb 19;15(1):51–55. doi: 10.1007/BF00563557. [DOI] [PubMed] [Google Scholar]
  3. Ala-Hurula V., Myllylä V. V., Arvela P., Kärki N. T., Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol. 1979 Nov;16(5):355–360. doi: 10.1007/BF00605636. [DOI] [PubMed] [Google Scholar]
  4. Bolme P., Edlund P. O., Eriksson M., Paalzow L., Winbladh B. Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories. Eur J Clin Pharmacol. 1979 Sep;16(2):133–139. doi: 10.1007/BF00563120. [DOI] [PubMed] [Google Scholar]
  5. Edlund P. O. Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1981 Nov 13;226(1):107–115. doi: 10.1016/s0378-4347(00)84211-5. [DOI] [PubMed] [Google Scholar]
  6. Ekbom K., Paalzow L., Waldenlind E. Low biological availability of ergotamine tartrate after oral dosing in cluster headache. Cephalalgia. 1981 Dec;1(4):203–207. doi: 10.1046/j.1468-2982.1981.0104203.x. [DOI] [PubMed] [Google Scholar]
  7. Hakkarainen H., Vapaatalo H., Gothoni G., Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979 Aug 18;2(8138):326–328. doi: 10.1016/s0140-6736(79)90343-x. [DOI] [PubMed] [Google Scholar]
  8. Ibraheem J. J., Paalzow L., Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol. 1982;23(3):235–240. doi: 10.1007/BF00547560. [DOI] [PubMed] [Google Scholar]
  9. Knudsen F. U. Plasma-diazepam in infants after rectal administration in solution and by suppository. Acta Paediatr Scand. 1977 Sep;66(5):563–567. doi: 10.1111/j.1651-2227.1977.tb07947.x. [DOI] [PubMed] [Google Scholar]
  10. Little P. J., Jennings G. L., Skews H., Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982 Jun;13(6):785–790. doi: 10.1111/j.1365-2125.1982.tb01866.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meier J., Schreier E. Human plasma levels of some anti-migraine drugs. Headache. 1976 Jul;16(3):96–104. doi: 10.1111/j.1526-4610.1976.hed1603096.x. [DOI] [PubMed] [Google Scholar]
  12. OSTFELD A. M. A study of migraine pharmacotherapy. Am J Med Sci. 1961 Feb;241:192–198. doi: 10.1097/00000441-196102000-00006. [DOI] [PubMed] [Google Scholar]
  13. Schmidt R., Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7(3):213–216. doi: 10.1007/BF00560383. [DOI] [PubMed] [Google Scholar]
  14. Tfelt-Hansen P., Eickhoff J. H., Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol (Copenh) 1980 Aug;47(2):151–156. doi: 10.1111/j.1600-0773.1980.tb01855.x. [DOI] [PubMed] [Google Scholar]
  15. Waters W. E. Controlled clinical trial of ergotamine tartrate. Br Med J. 1970 May 9;2(5705):325–327. doi: 10.1136/bmj.2.5705.325. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES